Lusaka, Zambia – July 16-19, 2024
Landing Med, a trailblazer in health technology, has been recognized as the only Asian company invited to participate in the prestigious Ending Preventable Maternal Mortality (EPMM) and Every Newborn Action Plan (ENAP) event, co-organized by the World Health Organization (WHO), United Nations Population Fund (UNFPA), and UNICEF in Lusaka, Zambia, from July 16 to July 19, 2024.
This invitation is a major milestone for Landing Med, underscoring its cutting-edge contributions to maternal and newborn health, particularly through the use of artificial intelligence (AI) in preventing cervical cancer in low-resource settings. It highlights the company's role as a key innovator in global health, committed to transforming care delivery in underserved regions.
The conference brought together international experts, policymakers, and healthcare leaders across Africa to accelerate progress toward achieving the United Nations’ Sustainable Development Goals (SDGs). The event's primary focus was to drive collaborative action to reduce maternal mortality and ensure that every newborn survives and thrives, with a special emphasis on addressing health disparities in low-income regions.
At the forum, Landing Med’s Head of Global Marketing, Lan Wang, delivered an impactful presentation on the company's AI-powered cervical cancer screening solution, which has demonstrated outstanding success in rural, low-resource settings across China. This solution directly addresses the global burden of cervical cancer, which disproportionately impacts women in developing countries—especially in Sub-Saharan Africa, where cervical cancer rates are among the highest in the world.
Landing Med’s AI-driven solution stands out due to its scalability, affordability, and ability to enhance early detection of cervical cancer, a critical factor in preventing the disease from reaching advanced stages in women with limited access to healthcare. With traditional diagnostic methods often unreliable or unavailable in many underserved areas, Landing Med’s AI cytology platform offers a reliable alternative in regions where the number of qualified pathologists is severely limited.
“Landing Med has been at the forefront of applying AI in healthcare since 2016. We have screened over 10 million women and our results have been scientifically validated across numerous studies,” said Lan Wang, Head of Global Marketing at Landing Med. “Our robust cytology cloud platform and technologies offer a cost-effective, scalable, and more accurate method of screening, which can be deployed even in the most remote areas. Being part of this conference provides us with the opportunity to highlight how AI can transform cervical cancer screening, particularly in regions where there is a severe shortage of pathology professionals.”
Landing Med’s participation at the EPMM and ENAP event marks the company as a leader in utilizing AI technology to address some women’s health in rural areas. The conference brought together global experts to discuss innovations in maternal and newborn health, and the company’s AI-driven cervical cancer prevention technology was seen as a key part of the future of healthcare in low-resource settings.
The AI platform is already proving to be an essential tool in countries where healthcare infrastructure is limited, and the need for early detection of cervical cancer is urgent. In Sub-Saharan Africa, where the incidence of cervical cancer is the world’s highest, this technology has the potential to save thousands of lives annually.
“Our mission is to ensure that all women, regardless of where they live, have access to affordable and high quality cervical cancer screenings,” Wang added. “By using AI, we can make this a reality, and our presence at this global forum allows us to contribute to the wider conversation about how digital health solutions can help meet the SDGs, particularly in reproductive health.”
As global attention increasingly turns toward achieving the SDGs, Landing Med is poised to play a critical role in shaping the future of global health. By expanding its AI screening solution to other resource-constrained regions, the company is well-positioned to contribute significantly to the global effort to reduce preventable deaths from cervical cancer.
“Collaboration is key in overcoming global health challenges,” said Wang. “We are committed to expanding our impact through partnerships with governments, NGOs, and healthcare providers around the world. Our goal is to ensure that this technology reaches women who need it most.”
Landing Med’s AI-driven cervical cancer prevention platform represents a pioneering solution in the fight against preventable maternal mortality and cancer-related deaths. As the company looks ahead, it remains focused on scaling its technological innovations to meet the needs of the world’s most vulnerable populations and contributing to the achievement of the SDGs in maternal health.
CN
